Last Updated:
Mounjaro targets GLP-1 and GIP hormones to aid weight loss.
In hope for lakhs battling obesity and diabetes, US multinational pharmaceutical company Eli Lilly has launched its weight loss drug, Mounjaro, in India. The drug, already making waves in Europe and the United States, has secured approval from the Central Drugs Standard Control Organisation (CDSCO) for being sold in the Indian market.
The arrival of Mounjaro comes at a time when obesity and diabetes pose significant public health challenges across the country, driving demand for effective treatments, and the introduction of this drug is being hailed as a potential game-changer.
Eli Lilly has priced Mounjaro at approximately Rs 4,375 ($50) for a single 5 mg injection, while the 2.5 mg variant costs Rs 3,500 ($40.54). For those requiring the 5 mg dosage regularly, the monthly expense could exceed Rs 16,000, which may put the drug out of reach for many without adequate insurance coverage.
Despite its high price, demand for the medication is expected to be robust given the rising prevalence of obesity- health concerns in the country.
Medical experts believe Mounjaro offers a significant advantage over existing weight-loss drugs. According to Dr Manisha Arora, as reported in The Indian Express, the drug mimics two key hormones: Glucagon-Like Peptide-1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP). These hormones play a critical role in regulating blood sugar levels, suppressing hunger, and slowing digestion, ultimately leading to a feeling of fullness and reduced food intake.
This dual-action mechanism sets Mounjaro apart from other widely used weight-loss medications such as Ozempic, which targets only the GLP-1 hormone.
Mounjaro is primarily intended for adults with Type 2 diabetes and individuals struggling with obesity. It has been described as particularly beneficial for those suffering from both conditions simultaneously. However, the drug should only be taken under medical supervision and is not suitable for certain groups, including:
While the high cost of Mounjaro may limit its accessibility, its potential impact on obesity and diabetes management could pave the way for improved health outcomes.
